Atlas Trials

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Clinical trial NCT01425970 · TERMINATED

Trial details

NCT number
NCT01425970
Sponsor
Bristol-Myers Squibb
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatitis C
Start date
2012-05-01
Primary completion
2013-08-01
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.